Reported Earnings • Jul 29
First quarter 2027 earnings released: ₹0.07 loss per share (vs ₹0.16 profit in 1Q 2026) First quarter 2027 results: ₹0.07 loss per share (down from ₹0.16 profit in 1Q 2026). Revenue: ₹96.0m (up 11% from 1Q 2026). Net loss: ₹4.56m (down 146% from profit in 1Q 2026). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Duyuru • Jul 28
Zenotech Laboratories Limited, Annual General Meeting, Sep 25, 2026 Zenotech Laboratories Limited, Annual General Meeting, Sep 25, 2026, at 10:30 Indian Standard Time. Duyuru • Jul 13
Zenotech Laboratories Limited to Report Q1, 2027 Results on Jul 28, 2026 Zenotech Laboratories Limited announced that they will report Q1, 2027 results on Jul 28, 2026 Reported Earnings • May 01
Full year 2026 earnings released: ₹0.18 loss per share (vs ₹0.92 profit in FY 2025) Full year 2026 results: ₹0.18 loss per share (down from ₹0.92 profit in FY 2025). Revenue: ₹459.2m (up 18% from FY 2025). Net loss: ₹10.7m (down 119% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Duyuru • Apr 23
Zenotech Laboratories Limited to Report Q4, 2026 Results on Apr 29, 2026 Zenotech Laboratories Limited announced that they will report Q4, 2026 results on Apr 29, 2026 New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin). Revenue is less than US$5m (₹419m revenue, or US$4.5m). Market cap is less than US$100m (₹2.81b market cap, or US$30.4m). Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹42.63, the stock trades at a trailing P/E ratio of 77.4x. Average trailing P/E is 57x in the Biotechs industry in India. Total loss to shareholders of 13% over the past three years. Reported Earnings • Jan 24
Third quarter 2026 earnings released: EPS: ₹0.32 (vs ₹0.28 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.32 (up from ₹0.28 in 3Q 2025). Revenue: ₹132.8m (up 25% from 3Q 2025). Net income: ₹19.3m (up 14% from 3Q 2025). Profit margin: 14% (down from 16% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Duyuru • Jan 24
Zenotech Laboratories Limited Announces Cessation of Chintan Jitendra Shah as Independent Director, Chairman of the Nomination and Remuneration Committee, Member of Audit Committee/ Stakeholders Relationship Committee and Reconstitution of Board Committees Zenotech Laboratories Limited announced that the second term of office of Mr. Chintan Jitendra Shah (DIN: 07325664) as an Independent Director of the Company will end on January 26, 2026. Accordingly, he will cease to be an Independent Director, Chairman of the Nomination and Remuneration Committee, Member of Audit Committee/Stakeholders Relationship Committee, with effect from January 26, 2026. The company has announced the reconstitution of its board committees, which includes the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, effective from January 27, 2026. The changes involve the appointment of Smt. Jagruti Prashant Sheth as the Chairperson of the Audit Committee, Mr. Premal Hemant Gandhi as the Chairman of the Nomination and Remuneration Committee, and Mr. Jignesh Anantray Goradia as the Chairman of the Stakeholders Relationship Committee. Duyuru • Jan 16
Zenotech Laboratories Limited to Report Q3, 2026 Results on Jan 23, 2026 Zenotech Laboratories Limited announced that they will report Q3, 2026 results on Jan 23, 2026 Reported Earnings • Nov 02
Second quarter 2026 earnings released: ₹0.14 loss per share (vs ₹0.22 profit in 2Q 2025) Second quarter 2026 results: ₹0.14 loss per share (down from ₹0.22 profit in 2Q 2025). Revenue: ₹119.4m (up 31% from 2Q 2025). Net loss: ₹8.37m (down 162% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Duyuru • Oct 22
Zenotech Laboratories Limited to Report Q2, 2026 Results on Oct 31, 2025 Zenotech Laboratories Limited announced that they will report Q2, 2026 results at 3:30 PM, Indian Standard Time on Oct 31, 2025 Duyuru • Jul 29
Zenotech Laboratories Limited, Annual General Meeting, Sep 26, 2025 Zenotech Laboratories Limited, Annual General Meeting, Sep 26, 2025, at 10:30 Indian Standard Time. Reported Earnings • Jul 29
First quarter 2026 earnings released: EPS: ₹0.16 (vs ₹0.21 in 1Q 2025) First quarter 2026 results: EPS: ₹0.16 (down from ₹0.21 in 1Q 2025). Revenue: ₹102.3m (up 11% from 1Q 2025). Net income: ₹9.90m (down 23% from 1Q 2025). Profit margin: 9.7% (down from 14% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Duyuru • Jul 21
Zenotech Laboratories Limited to Report Q1, 2026 Results on Jul 28, 2025 Zenotech Laboratories Limited announced that they will report Q1, 2026 results on Jul 28, 2025 Valuation Update With 7 Day Price Move • May 19
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹64.47, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 56x in the Biotechs industry in India. Total returns to shareholders of 17% over the past three years. Reported Earnings • Apr 30
Full year 2025 earnings released: EPS: ₹0.92 (vs ₹1.36 in FY 2024) Full year 2025 results: EPS: ₹0.92 (down from ₹1.36 in FY 2024). Revenue: ₹405.2m (up 10% from FY 2024). Net income: ₹56.1m (down 32% from FY 2024). Profit margin: 14% (down from 23% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Duyuru • Apr 21
Zenotech Laboratories Limited to Report Q4, 2025 Results on Apr 25, 2025 Zenotech Laboratories Limited announced that they will report Q4, 2025 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹61.42, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 51x in the Biotechs industry in India. Total returns to shareholders of 14% over the past three years. Reported Earnings • Jan 29
Third quarter 2025 earnings released: EPS: ₹0.28 (vs ₹0.55 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.28 (down from ₹0.55 in 3Q 2024). Revenue: ₹116.1m (up 14% from 3Q 2024). Net income: ₹16.9m (down 50% from 3Q 2024). Profit margin: 15% (down from 33% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Duyuru • Jan 18
Zenotech Laboratories Limited to Report Q3, 2025 Results on Jan 28, 2025 Zenotech Laboratories Limited announced that they will report Q3, 2025 results on Jan 28, 2025 Duyuru • Oct 24
Zenotech Laboratories Limited Appoints Dr. Sachin Laxmanappa Gavandare as Chief Executive Officer (Key Managerial Personnel) Zenotech Laboratories Limited appointed Dr. Sachin Laxmanappa Gavandare as Chief Executive Officer (Key Managerial Personnel) of the Company with immediate effect. He holds Ph .D (Pharmacy) from Shri JJT University, Rajasthan and Masters in Pharmacy (Pharmaceutical Technology) from Andhra University, Visakhapatnam, Andhra Pradesh, MBA (Operations Management) from ICFAI University, Tripura . He has over 19 years of rich experience in the pharma industry. He was earlier associate d with CuraTeQ Biologics (An Aurobindo Pharma subsidiary company), Mankind Pharma Limited, Dr. Reddy' s Laboratories Limited, lntas Biopharmaceuticals Limited, Cipla Limited and Concept Pharmaceuticals Limited . He held various positions and assignments in production, quality and operations management leading the teams for organizational objectives. He has acquired expertise in driving product manufacturing and quality improvement activities. Reported Earnings • Oct 24
Second quarter 2025 earnings released: EPS: ₹0.22 (vs ₹0.46 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.22 (down from ₹0.46 in 2Q 2024). Revenue: ₹101.1m (down 5.6% from 2Q 2024). Net income: ₹13.5m (down 53% from 2Q 2024). Profit margin: 13% (down from 27% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Duyuru • Oct 17
Zenotech Laboratories Limited to Report First Half, 2025 Results on Oct 23, 2024 Zenotech Laboratories Limited announced that they will report first half, 2025 results on Oct 23, 2024 New Risk • Sep 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (₹386m revenue, or US$4.6m). Market cap is less than US$100m (₹6.20b market cap, or US$73.9m). Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹85.95, the stock trades at a trailing P/E ratio of 70.4x. Average trailing P/E is 34x in the Biotechs industry in India. Total returns to shareholders of 66% over the past three years. Duyuru • Aug 26
Zenotech Laboratories Limited, Annual General Meeting, Sep 27, 2024 Zenotech Laboratories Limited, Annual General Meeting, Sep 27, 2024, at 10:35 Indian Standard Time. Reported Earnings • Jul 27
First quarter 2025 earnings released: EPS: ₹0.21 (vs ₹0.35 in 1Q 2024) First quarter 2025 results: EPS: ₹0.21 (down from ₹0.35 in 1Q 2024). Revenue: ₹102.5m (up 7.1% from 1Q 2024). Net income: ₹12.9m (down 40% from 1Q 2024). Profit margin: 13% (down from 22% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Duyuru • Jul 19
Zenotech Laboratories Limited to Report Q1, 2025 Results on Jul 26, 2024 Zenotech Laboratories Limited announced that they will report Q1, 2025 results on Jul 26, 2024 Duyuru • May 18
Zenotech Laboratories Limited Announces Resignation of Devendra Chandrakant Shenvi Kenkre as Chief Executive Officer, Effective August 12, 2024 Zenotech Laboratories Limited announced that Mr. Devendra Chandrakant Shenvi Kenkre has tendered his resignation as the Chief Executive Officer of the Company vide his letter dated May 17, 2024 due to personal reasons. His last working day as the Chief Executive Officer would be on or before August 12, 2024. Reported Earnings • May 03
Full year 2024 earnings released: EPS: ₹1.36 (vs ₹1.90 in FY 2023) Full year 2024 results: EPS: ₹1.36 (down from ₹1.90 in FY 2023). Revenue: ₹418.4m (up 7.2% from FY 2023). Net income: ₹83.0m (down 28% from FY 2023). Profit margin: 20% (down from 30% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 14% per year. Duyuru • Apr 26
Zenotech Laboratories Limited to Report Q4, 2024 Results on May 01, 2024 Zenotech Laboratories Limited announced that they will report Q4, 2024 results on May 01, 2024 Board Change • Apr 25
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Jagruti Sheth was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹68.92, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 86% over the past three years. Reported Earnings • Jan 30
Third quarter 2024 earnings released: EPS: ₹0.55 (vs ₹0.23 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.55 (up from ₹0.23 in 3Q 2023). Revenue: ₹112.3m (up 41% from 3Q 2023). Net income: ₹33.6m (up 143% from 3Q 2023). Profit margin: 30% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Duyuru • Jan 18
Zenotech Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024 Zenotech Laboratories Limited announced that they will report Q3, 2024 results on Jan 29, 2024 Valuation Update With 7 Day Price Move • Jan 15
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹78.84, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 59x in the Biotechs industry in India. Total returns to shareholders of 139% over the past three years. Reported Earnings • Nov 01
Second quarter 2024 earnings released: EPS: ₹0.46 (vs ₹0.45 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.46 (up from ₹0.45 in 2Q 2023). Revenue: ₹117.2m (up 18% from 2Q 2023). Net income: ₹28.3m (up 2.5% from 2Q 2023). Profit margin: 24% (down from 28% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹62.12, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 82% over the past three years. Duyuru • Oct 20
Zenotech Laboratories Limited to Report Q2, 2024 Results on Oct 30, 2023 Zenotech Laboratories Limited announced that they will report Q2, 2024 results on Oct 30, 2023 New Risk • Oct 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (30% net profit margin). Revenue is less than US$5m (₹390m revenue, or US$4.7m). Market cap is less than US$100m (₹3.82b market cap, or US$45.9m). Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹66.55, the stock trades at a trailing P/E ratio of 35.1x. Average trailing P/E is 30x in the Biotechs industry in India. Total returns to shareholders of 80% over the past three years. Duyuru • Sep 02
Zenotech Laboratories Limited, Annual General Meeting, Sep 29, 2023 Zenotech Laboratories Limited, Annual General Meeting, Sep 29, 2023, at 10:30 Indian Standard Time. Duyuru • Jul 26
Zenotech Laboratories Limited to Report Q1, 2024 Results on Aug 01, 2023 Zenotech Laboratories Limited announced that they will report Q1, 2024 results on Aug 01, 2023 Reported Earnings • Apr 30
Full year 2023 earnings released: EPS: ₹1.90 (vs ₹3.63 in FY 2022) Full year 2023 results: EPS: ₹1.90 (down from ₹3.63 in FY 2022). Revenue: ₹404.1m (up 23% from FY 2022). Net income: ₹115.9m (down 48% from FY 2022). Profit margin: 29% (down from 67% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Jagruti Sheth was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jan 20
Zenotech Laboratories Limited to Report Q3, 2023 Results on Jan 27, 2023 Zenotech Laboratories Limited announced that they will report Q3, 2023 results on Jan 27, 2023 Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improved over the past week After last week's 16% share price gain to ₹66.35, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 36x in the Biotechs industry in Asia. Total returns to shareholders of 161% over the past three years. Duyuru • Oct 20
Zenotech Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022 Zenotech Laboratories Limited announced that they will report Q2, 2023 results on Oct 28, 2022 Duyuru • Aug 28
Zenotech Laboratories Limited, Annual General Meeting, Sep 24, 2022 Zenotech Laboratories Limited, Annual General Meeting, Sep 24, 2022, at 10:30 Indian Standard Time. Reported Earnings • Jul 23
First quarter 2023 earnings released: EPS: ₹0.62 (vs ₹0.57 in 1Q 2022) First quarter 2023 results: EPS: ₹0.62 (up from ₹0.57 in 1Q 2022). Revenue: ₹124.1m (up 40% from 1Q 2022). Net income: ₹37.7m (up 7.8% from 1Q 2022). Profit margin: 30% (down from 39% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jul 15
Zenotech Laboratories Limited to Report Q1, 2023 Results on Jul 22, 2022 Zenotech Laboratories Limited announced that they will report Q1, 2023 results on Jul 22, 2022 Valuation Update With 7 Day Price Move • Jun 28
Investor sentiment improved over the past week After last week's 19% share price gain to ₹57.70, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 32x in the Biotechs industry in Asia. Total returns to shareholders of 272% over the past three years. Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹49.45, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total returns to shareholders of 151% over the past three years. Reported Earnings • May 01
Full year 2022 earnings released: EPS: ₹3.63 (vs ₹0.20 loss in FY 2021) Full year 2022 results: EPS: ₹3.63 (up from ₹0.20 loss in FY 2021). Revenue: ₹371.9m (up 92% from FY 2021). Net income: ₹221.8m (up ₹233.9m from FY 2021). Profit margin: 60% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Apr 23
Zenotech Laboratories Limited to Report Q4, 2022 Results on Apr 29, 2022 Zenotech Laboratories Limited announced that they will report Q4, 2022 results on Apr 29, 2022 Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improved over the past week After last week's 21% share price gain to ₹68.95, the stock trades at a trailing P/E ratio of 45.6x. Average trailing P/E is 33x in the Biotechs industry in Asia. Total returns to shareholders of 213% over the past three years. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improved over the past week After last week's 18% share price gain to ₹60.30, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 40x in the Biotechs industry in Asia. Total returns to shareholders of 63% over the past three years. Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improved over the past week After last week's 16% share price gain to ₹49.70, the stock trades at a trailing P/E ratio of 53.3x. Average trailing P/E is 42x in the Biotechs industry in Asia. Total returns to shareholders of 36% over the past three years. Reported Earnings • Oct 24
Second quarter 2022 earnings released: EPS ₹0.16 (vs ₹0.34 loss in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹80.1m (up 173% from 2Q 2021). Net income: ₹9.46m (up ₹30.2m from 2Q 2021). Profit margin: 12% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 25
First quarter 2022 earnings released: EPS ₹0.57 (vs ₹0.20 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹99.6m (up 152% from 1Q 2021). Net income: ₹35.0m (up ₹47.3m from 1Q 2021). Profit margin: 35% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 03
Full year 2021 earnings released: ₹0.20 loss per share (vs ₹1.77 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: ₹228.5m (down 12% from FY 2020). Net loss: ₹12.2m (down 111% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 17
New 90-day high: ₹39.50 The company is up 49% from its price of ₹26.55 on 19 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Duyuru • Jan 24
Zenotech Laboratories Limited Appoints Devendra Chandrakant S. Kenkre as Chief Executive Officer Zenotech Laboratories Limited that the Board of Directors of the Company, at their meeting held on January 23, 2021 have appointed Mr. Devendra Chandrakant S. Kenkre as the Chief Executive Officer of the Company with effective from January 23, 2021. He has over 29 years of experience in the pharma 1ndustry. He was earlier associated with E Merck India Limited and Sovereign Pharma Private Limited. Duyuru • Jan 13
Zenotech Laboratories Limited to Report Q3, 2021 Results on Jan 23, 2021 Zenotech Laboratories Limited announced that they will report Q3, 2021 results on Jan 23, 2021 Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 20% share price gain to ₹33.90, the stock is trading at a trailing P/E ratio of 47.8x, up from the previous P/E ratio of 39.8x. This compares to an average P/E of 59x in the Biotechs industry in Asia. Total return to shareholders over the past three years is a loss of 28%. Valuation Update With 7 Day Price Move • Nov 27
Market bids up stock over the past week After last week's 17% share price gain to ₹30.80, the stock is trading at a trailing P/E ratio of 43.5x, up from the previous P/E ratio of 37x. This compares to an average P/E of 59x in the Biotechs industry in Asia. Total return to shareholders over the past three years is a loss of 41%. Reported Earnings • Nov 02
Second quarter 2021 earnings released: ₹0.34 loss per share The company reported a poor second quarter result with weaker earnings, revenues and control over expenses. Second quarter 2021 results: Revenue: ₹39.6m (down 45% from 2Q 2020). Net loss: ₹20.7m (down 199% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 06
New 90-day high: ₹36.55 The company is up 66% from its price of ₹22.00 on 08 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. 
